RecruitingNot ApplicableNCT04940936

Shared Decision Making on Radiation Dose for Lung Malignancies

Shared Decision Making on Radiation Dose for Stereotactic Body Radiotherapy of Malignancies Located Less Than 1 cm From the Thoracic Wall. A Randomized Trial

Sponsor

Vejle Hospital

Enrollment

40 participants

Start Date

Nov 12, 2021

Study Type

INTERVENTIONAL

Conditions

Decision Making, Shared Stereotactic Body Radiation Therapy

Summary

A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on the dose of stereotactic body radiation therapy (SBRT) for lung tumors located less than 1 cm from the thoracic wall. Hypothesis: The use of a PtDA will increase the extent of Shared Decision Making (SDM) during the consultation and result in patients being more directly involved in the planning of their treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study explores whether involving patients in choosing the radiation dose for their lung cancer or lung metastasis treatment (through shared decision-making) leads to better satisfaction and quality of life compared to the doctor choosing the dose alone. **You may be eligible if...** - You are 18 or older - You have non-small cell lung cancer or a lung metastasis from another cancer, located near the chest wall - You are eligible for stereotactic body radiation therapy (SBRT) — a precise, high-dose, short-course radiation treatment - You can read and understand Danish - Your life expectancy is more than 6 months **You may NOT be eligible if...** - You have previously received radiation to the chest area (unless a new radiation plan is possible) - You do not read Danish - Your performance status or life expectancy is too low Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.